The last recurrence in the long-term study occurred at 5.4 years, leading researchers to be more comfortable using the term ...

Vertex Pharmaceuticals and CRISPR Therapeutics' gene-editing drug is the only sickle cell disease gene therapy on the market for young children.

During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...

In a Phase III trial, divarasib bested first-generation drugs Lumakras and Krazati, which the firm said could make it a new standard of care in KRAS G12C-mutated NSCLC.

The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...

The agency expects to issue decisions on Vyondys 53 and Amondys 45, which missed their primary endpoint in a confirmatory trial, by February 2027.

The program will help make genetic counselors available to any provider across different medical specialties in Tennessee and ...

Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...

The Phase I/II China-based trial will test the combination in patients with PD-L1-positive, EGFR mutated tumors.

Three cases suggest some clinicians lack understanding of relatively common autosomal recessive disorders and are ...